Nanovibronix (FEED) vs. The Competition Head-To-Head Review

Nanovibronix (NASDAQ:FEED) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Nanovibronix to similar companies based on the strength of its valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Profitability

This table compares Nanovibronix and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Nanovibronix Competitors	-672.41%	-133.75%	-59.01%

Risk & Volatility

Nanovibronix has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s rivals have a beta of 1.76, suggesting that their average share price is 76% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nanovibronix and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Nanovibronix Competitors	77	76	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 51.09%. Given Nanovibronix’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 5.2% of Nanovibronix shares are owned by company insiders. Comparatively, 18.4% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Nanovibronix and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nanovibronix	$2.56 million	-$3.70 million	-0.07
Nanovibronix Competitors	$59.54 million	-$32.15 million	4.18

Nanovibronix’s rivals have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Nanovibronix rivals beat Nanovibronix on 7 of the 12 factors compared.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.